STOCK TITAN

iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
iCAD, Inc. (NASDAQ: ICAD) reports annual recurring revenue of $8.7 million, a 15% increase year-over-year. Full-year operating cash flow improved to ($5) million from ($12.8) million. Despite a 13% decrease in total revenues for 2023, the company saw a rise in gross profit margin to 91% in Q4 2023. The GAAP net loss from continuing operations improved to ($0.5) million in Q4 2023. iCAD's President and CEO, Dana Brown, highlighted strong execution and progress towards the company's transformation plan. iCAD remains optimistic about its cash resources and future operations.
Positive
  • Annual recurring revenue increased by 15% year-over-year to $8.7 million.
  • Full-year operating cash flow improved to ($5) million from ($12.8) million.
  • Total revenues for Q4 2023 were $4.7 million, up 2% from the previous year.
  • Gross profit margin % increased to 91% in Q4 2023 from 84% in the previous year.
  • GAAP net loss from continuing operations improved to ($0.5) million in Q4 2023.
  • iCAD's President and CEO, Dana Brown, emphasized progress towards the company's transformation plan.
  • Cash and cash equivalents stood at $21.7 million as of December 31, 2023.
  • The company believes it has sufficient cash resources to fund its current planned operations without the need for additional funding.
Negative
  • Total revenues for full-year 2023 decreased by 13%.
  • Non-GAAP adjusted EBITDA showed a loss of ($0.4) million in Q4 2023.
  • Product revenue decreased by 21.3% year-over-year for the twelve months ended December 31, 2023.

The reported Annual Recurring Revenue (ARR) growth of 15% year-over-year for iCAD Inc. is a positive indicator of the company's ability to retain and potentially expand its customer base over time. ARR is a critical metric for companies with a subscription-based revenue model as it provides a more predictable and stable revenue stream. The increase in ARR, coupled with the improvement in operating cash flow from ($12.8) million to ($5) million, suggests that iCAD is moving towards operational efficiency and better cash management.

However, the full-year revenue decline of 13% raises concerns about the company's market position and competitive dynamics. While the gross profit margin remains consistent at 85%, indicating stable production costs relative to sales, the drop in product revenue by 21.3% could reflect either a decrease in demand or increased competition. Investors should monitor subsequent quarters to determine if this is an ongoing trend or a one-time fluctuation.

The improvement in GAAP Net Loss from continuing operations suggests that the company's cost-cutting measures or operational adjustments are having a positive effect on the bottom line. However, a continuous net loss indicates that the company has not yet reached profitability, which is an essential factor for long-term sustainability.

From a market perspective, iCAD's focus on AI-powered solutions for cancer detection positions the company within a high-growth sector. The healthcare industry's increasing adoption of AI technologies for diagnostic accuracy and efficiency could serve as a tailwind for iCAD's offerings. The reported reading of over 40 million mammograms, with nearly 30% being tomosynthesis, demonstrates the company's significant footprint in the diagnostic imaging market.

The gross profit margin of 91% in Q4, up from 84%, is particularly noteworthy as it suggests a strong value proposition and pricing power for iCAD's products and services. However, it is essential to juxtapose this against the overall revenue decline to assess the company's market strategy effectiveness.

Given the company's statement about a three-phased transformation plan and investment in growth initiatives, stakeholders should look for signs of innovation and market expansion in future reports. The ability of iCAD to capitalize on its patient-centric mission and leverage its technological advancements will be crucial for its continued growth and market share acquisition.

Within the medical technology sector, iCAD's focus on early cancer detection through AI is a strategic advantage. The high gross profit margins indicate that iCAD's products have substantial intellectual property value and require a lower cost of goods sold relative to their selling price. This is often the case with software and technology-driven solutions, which can scale effectively once developed.

The issuance of 1,057,814 shares in at-the-market (ATM) offerings and the sale of Xoft resulting in net cash proceeds of $4.5 million reflect strategic financial moves to bolster the company's cash position. The management's confidence in funding current operations without additional fundraising is a positive signal to investors about the company's financial strategy and liquidity status.

For stakeholders, the key will be to monitor how effectively iCAD can translate its technological capabilities into commercial success. The company's ability to drive adoption of its AI-powered solutions in a competitive healthcare market will be critical. Future regulatory approvals and clinical trial outcomes will also play a significant role in shaping the company's trajectory.

Annual Recurring Revenue of $8.7 million, an increase of 15% year-over-year
Full-Year Operating Cash Flow ($5) million vs. ($12.8) million prior year
Year ending cash balance of $21.7M

NASHUA, N.H., March 12, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, today announced results for its fiscal fourth quarter and full year ended December 31, 2023, as compared to the corresponding period of the last fiscal year.

Fourth Quarter 2023 Financial Highlights:

  • Total ARR was $8.7 million, up 15%
  • Total revenues were $4.7 million, up 2%
  • Gross Profit Margin % was 91%, up from 84%
  • GAAP Net Loss from continuing operations ($0.5) million, improvement from ($2.3) million
  • Operating cash flow was ($1.5) million, improvement from ($3.1) million

Full Year 2023 Financial Highlights:

  • Total revenues were $17.3 million, down 13%
  • Gross Profit Margin % was 85%, flat year-over-year
  • GAAP Net Loss from continuing operations ($7) million, improvement from ($9.9) million
  • Operating cash flow was ($5) million, improvement from ($12.8) million

“Reflecting on solid Q4 results, iCAD has demonstrated strong execution and progress towards our three-phased transformation plan - realigning our base, strengthening our foundation, and investing in growth initiatives – allowing us to drive towards our patient-centric mission of creating a world where cancer can’t hide,” said Dana Brown, President and CEO, iCAD. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, of which nearly 30% are tomosynthesis.

Three Months Ended December 31, 2023 Financial Results

Total revenue for the fourth quarter of 2023 was $4.7 million, an increase of $0.1 million, or 2%, as compared to the fourth quarter of 2022.

(in 000’s)Three months ended December 31, 
 2023  2022  $ Change  % Change 
Product revenue$2,970  $2,754  $216   7.8%
Service and supplies revenue 1,771   1,881   (110)  -5.8%
Total revenue$4,741  $4,635  $106   2.3%
                

Gross Profit: Gross profit for the fourth quarter of 2023 was $4.3 million, or 91% of revenue, as compared to $3.9 million, or 84% of revenue, in the fourth quarter of 2022.

Operating Expenses: Total operating expenses for the fourth quarter of 2023 were $5.0 million, a 22% decrease from $6.5 million in the fourth quarter of 2022.

GAAP Net Loss from continuing operations: Net loss from continuing operations for the fourth quarter of 2023 was ($0.5) million, or ($0.02) per diluted share, as compared to a net loss of ($2.3) million, or ($0.09) per diluted share, for the fourth quarter of 2022.

Non-GAAP Adjusted Net Loss from continuing operations: Non-GAAP Adjusted Net Loss from continuing operations, a non-GAAP financial measure as defined below, for the fourth quarter of 2023 was ($0.5) million, or ($0.02) per diluted share, as compared to a Non-GAAP Adjusted Net Loss of ($2.2) million, or ($0.09) per diluted share, for the fourth quarter of 2022. Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss results for the three-month periods ended December 31, 2023 and 2022, respectively.

Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA, a non-GAAP financial measure as defined below, for the fourth quarter of 2023 was a loss of ($0.4) million compared to a loss of $(2.1) million in the fourth quarter of 2022. Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA results for the three-month periods ended December 31, 2023 and 2022, respectively.

Twelve Months Ended December 31, 2023 Financial Results

Total revenue for the twelve months ended December 31, 2023 was $17.3 million, a decrease of $2.5 million, or 13%, as compared to the twelve months ended December 31, 2022.

(in 000’s)Twelve months ended December 31,
 
 2023
  2022
  $ Change
  % Change
 
Product revenue$9,930  $12,620  $(2,690)  -21.3%
Service and supplies revenue 7,388   7,182   206   2.9%
Total revenue$17,318  $19,802  $(2,484)  -12.5%
                

Gross Profit: Gross profit for the twelve months ended December 31, 2023 was $14.8 million, or 85% of revenue, as compared to $16.8 million, or 85% of revenue, for the twelve months ended December 31, 2022.

Operating Expenses: Total operating expenses for the twelve months ended December 31, 2023 were $22.5 million, a 17% decrease from $27.0 million for the twelve months ended December 31, 2022.

GAAP Net Loss from continuing operations: Net loss from continuing operations for the twelve months ended December 31, 2023 was ($7.0) million, or ($0.27) per diluted share, as compared to a net loss of ($9.9) million, or ($0.39) per diluted share, for the twelve months ended December 31, 2022.

Non-GAAP Adjusted Net Loss from continuing operations: Non-GAAP Adjusted Net Loss from continuing operations, a non-GAAP financial measure as defined below, for the twelve months ended December 31, 2023 was ($6.8) million, or ($0.27) per diluted share, as compared to a Non-GAAP Adjusted Net Loss of ($9.8) million, or ($0.39) per diluted share, for the twelve months ended December 31, 2022. Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss results for the twelve-month periods ended December 31, 2023 and 2022, respectively.

Non-GAAP Adjusted EBITDA: Non-GAAP Adjusted EBITDA, a non-GAAP financial measure as defined below, for the first twelve months of 2023 was a loss of ($5.9) million compared to a loss of $(8.1) million in the first twelve months of 2022. Please refer to the section entitled “Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP Net Loss to Non-GAAP Adjusted EBITDA results for the nine-month periods ended December 31, 2023 and 2022, respectively.

Cash and cash equivalents: Cash and cash equivalents were $21.7 million as of December 31, 2023. During the year ended December 31, 2023, the Company generated net proceeds of approximately $2.0 million from the issuance of 1,057,814 shares of common stock in at-the-market (ATM) offerings at a weighted average price of $2.18 per share. In addition, the Xoft sale in October 2023 resulted in net cash proceeds of $4.5 million. Accordingly, iCAD believes it has sufficient cash resources to fund its current planned operations with no need to raise additional funding. 

Conference Call:
A conference call will be held today, Tuesday, March 12, 2024 at 4:30 PM ET.

Use of Non-GAAP Financial Measures
In its quarterly news releases, conference calls, slide presentations or webcasts, the Company may use or discuss non-GAAP financial measures as defined by SEC Regulation G. The GAAP financial measures most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. When analyzing the Company’s operating performance, investors should not consider these non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP. The Company’s quarterly news releases containing such non-GAAP reconciliations can be found on the Investors section of the Company’s website at www.icadmed.com

About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com.

Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

CONTACTS

Media inquiries: pr@icadmed.com
Investor Inquiries: ir@icadmed.com

 
iCAD, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets
(In thousands, except for share data)
(Unaudited)
 
 December 31,  December 31, 
 2023  2022 
Assets       
Current assets:       
Cash and cash equivalents$21,670  $21,313 
Trade accounts receivable, net of allowance for credit losses of $277 and $100 as of December 31, 2023 and December 31, 2022, respectively 6,549   5,769 
Inventory, net 917   2,054 
Prepaid expenses and other current assets 699   1,571 
Current assets held for sale    7,534 
Total current assets$29,835  $38,241 
Property and equipment, net of accumulated depreciation of $1,045 and $850 as of December 31, 2023 and December 31, 2022, respectively 1,823   704 
Operating lease assets 461   670 
Other assets 692   19 
Intangible assets, net of accumulated amortization of $8,488 and $8,372 as of December 31, 2023 and December 31, 2022, respectively 148   264 
Goodwill 8,362   8,362 
Deferred tax assets 97   116 
Noncurrent assets held for sale    3,329 
Total assets$41,418  $51,705 
Liabilities and Stockholders’ Equity       
Current liabilities:       
Accounts payable$712  $1,446 
Accrued and other expenses 2,448   2,541 
Lease payable—current portion 188   217 
Deferred revenue—current portion 3,400   3,653 
Current held for sale    5,595 
Total current liabilities 6,748   13,452 
Lease payable, net of current 273   455 
Deferred revenue, net of current 974   393 
Deferred tax 6   6 
Noncurrent liabilities held for sale    2,497 
Total liabilities 8,001   16,803 
Commitments and Contingencies       
Stockholders’ equity:       
Preferred stock, $0.01 par value: authorized 1,000,000 shares; none issued.     
Common stock, $0.01 par value: authorized 60,000,000 shares; issued 26,540,030 and 25,446,407 as of December 31, 2023 and December 31, 2022, respectively; outstanding 26,354,199 and 25,260,576 as of December 31, 2023 and December 31, 2022, respectively. 265   254 
Additional paid-in capital 306,250   302,899 
Accumulated deficit (271,683)  (266,836)
Treasury stock at cost, 185,831 shares as of both December 31, 2023 and December 31, 2022 (1,415)  (1,415)
Total stockholders’ equity 33,417   34,902 
Total liabilities and stockholders’ equity$41,418  $51,705 
        


iCAD, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(In thousands, except for per share data)
(Unaudited)
 
 Three Months Ended  Twelve Months Ended 
 December 31,  December 31, 
 2023  2022  2023  2022 
Revenue:               
Products$2,970  $2,754  $9,930  $12,620 
Services 1,771   1,881   7,388   7,182 
Total revenue 4,741   4,635   17,318   19,802 
Cost of revenue:               
Products 287   405   1,387   1,658 
Services 109   301   1,060   1,217 
Amortization and depreciation 22   27   86   108 
Total cost of revenue 418   733   2,533   2,983 
Gross profit 4,323   3,902   14,785   16,819 
Operating expenses:               
Engineering and product development 1,252   1,134   5,161   5,493 
Marketing and sales 2,049   2,584   7,740   10,790 
General and administrative 1,675   2,713   9,324   10,517 
Amortization and depreciation 63   48   249   217 
Total operating expenses 5,039   6,479   22,474   27,017 
Loss from operations (716)  (2,577)  (7,689)  (10,198)
Other income/ (expense):               
Interest expense (14)  (2)  (16)  (10)
Interest income 201   124   729   213 
Other income (expense), net (6)      (14)  (39)
Other income (expense), net 181   122   699   164 
Loss before provision for income taxes (535)  (2,455)  (6,990)  (10,034)
Benefit (Provision) for tax expense (7)  116   (20)  116 
Loss from continuing operations (542)  (2,339)  (7,010)  (9,918)
Income (loss) from discontinued operations 1,904   (756)  2,163   (3,738)
Net loss and comprehensive loss$1,362  $(3,095) $(4,847) $(13,656)
Net loss per share:               
Loss from continuing operations, basic and diluted$(0.02) $(0.09) $(0.27) $(0.39)
Loss from discontinued operations, basic and diluted$0.07  $(0.03) $0.08  $(0.15)
Net loss per share, basic and diluted$0.05  $(0.12) $(0.19) $(0.54)
Weighted average number of shares used in computing loss per share: 26,323   25,260   25,613   25,202 
                


iCAD, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 
 For the Twelve Months ended  
 December 31, 
 2023  2022 
Cash flow from operating activities:       
Net loss$(4,847) $(13,656)
Adjustments to reconcile net loss to net cash used for operating activities:       
Gain on sale of business (2,592)   
Amortization 170   211 
Depreciation 239   310 
Non-cash lease expense 487   708 
Bad debt provision 177   732 
Stock-based compensation 1,316   1,686 
Deferred tax 20   (116)
Other, net (1   9 
Changes in operating assets and liabilities:       
Accounts receivable (1,751)  (739)
Inventory 1,489   (1,218)
Prepaid and other assets 972   1,152 
Accounts payable (1,086)  (806)
Accrued and other expenses (1,279)  (961)
Lease liabilities (484)  (767)
Deferred revenue 2,206   665 
Total adjustments (117)  866 
Net cash used for operating activities (4,964)  (12,790)
Cash flow from investing activities:       
Proceeds from sale of business, net of transaction costs 4,539    
Additions to patents, technology and other    (10)
Additions to property and equipment (942)  (524)
Capitalization of internal-use software (342)   
Net cash used for investing activities 3,255   (534)
Cash flow from financing activities:       
Issuance of common stock for cash, net 1,966    
Issuance of common stock pursuant to Employee Stock Purchase Plan    148 
Issuance of common stock pursuant to stock option plans 80   207 
Net cash provided by financing activities 2,046   355 
(Decrease) increase in cash and cash equivalents 337   (12,969)
Cash and cash equivalents, beginning of period 21,313   34,282 
Cash and cash equivalents, end of period$21,650  $21,313 
Supplemental disclosure of cash flow information:       
Interest paid$16  $9 
Amendment to right-of-use assets obtained in exchange for operating lease liabilities$  $3,011 
        

Reconciliation of Non-GAAP Financial Measures to Comparable GAAP Measures and Definitions

The Company reports its financial results in accordance with United States generally accepted accounting principles, or GAAP. However, management believes that in order to understand the Company’s short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and/or impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of the Company and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in the Company’s ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of the Company’s ongoing business with prior periods more difficult, obscure trends in ongoing operations or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing the Company’s financial and operational performance and comparing this performance to its peers and competitors.

Management defines “Non-GAAP Adjusted EBITDA” as the sum of GAAP Net Loss before provisions for interest expense, other income, stock-based compensation expense, depreciation and amortization, tax expense, severance, gain on sale of assets, loss on disposal of assets, acquisition and litigation related expenses. Management considers this non-GAAP financial measure to be an indicator of the Company’s operational strength and performance of its business and a good measure of its historical operating trends, in particular the extent to which ongoing operations impact the Company’s overall financial performance.

The non-GAAP financial measures do not replace the presentation of the Company’s GAAP financial results and should only be used as a supplement to, not as a substitute for, the Company’s financial results presented in accordance with GAAP. The Company has provided a reconciliation of each non-GAAP financial measure used in its financial reporting and investor presentations to the most directly comparable GAAP financial measure.

Management excludes each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:

  • Interest expense: The Company excludes interest expense which includes interest from the facility agreement, interest on capital leases and interest on the convertible debentures from its non-GAAP Adjusted EBITDA calculation.
  • Stock-based compensation expense: excluded as these are non-cash expenses that management does not consider part of ongoing operating results when assessing the performance of the Company’s business, and also because the total amount of expense is partially outside of the Company’s control as it is based on factors such as stock price volatility and interest rates, which may be unrelated to our performance during the period in which the expense is incurred.
  • Amortization and Depreciation: Purchased assets and intangibles are amortized over a period of several years and generally cannot be changed or influenced by management after they are acquired. Accordingly, these non-cash items are not considered by management in making operating decisions, and management believes that such expenses do not have a direct correlation to future business operations. Thus, including such charges does not accurately reflect the performance of the Company’s ongoing operations for the period in which such charges are incurred.
  • Severance and Furlough: The Company has incurred severance and furlough expenses in connection with restructuring and in connection with the separation of its former CEO. The Company excludes these items from its non-GAAP financial measures when evaluating its continuing business performance as such items can vary significantly and do not reflect expected future operating expenses. In addition, management believes that such items do not have a direct correlation to future business operations.
  • Loss on fair value of convertible debentures. The Company excludes this non-cash item as it is not considered by management in making operating decisions, and management believes that such item does not have a direct correlation to future business operations.
  • Litigation related: These expenses consist primarily of settlement, legal and other professional fees related to litigation. The Company excludes these costs from its non-GAAP measures primarily because the Company believes that these costs have no direct correlation to the core operations of the Company.
  • Loss on extinguishment of debt: The Company excludes this non-cash item as it is not considered by management in making operating decisions, and management believes that such item does not have a direct correlation to future business operations.

On occasion in the future, there may be other items, such as loss on extinguishment of debt, significant asset impairments, restructuring charges or significant gains or losses from contingencies that the Company may exclude if it believes that doing so is consistent with the goal of providing useful information to investors and management.

Definitions

Starting in the third quarter of 2023, the Company began reporting Annual Recurring Revenue (“ARR”) with each quarterly earnings announcement. The Company’s management believes this is a useful metric for purposes of assessing progress in transitioning to a subscription-based business model. ARR should be viewed independently of revenue and does not represent our revenue under U.S. GAAP on an annualized basis, as it is an operating metric that can be impacted by contract start dates, end dates, cancellations, and renewal rates. Subscription ARR is not intended to be a replacement for forecasts of revenue. The following are the variations of ARR the Company intends to present:

  1. Total ARR (T-ARR) represents the annualized value of subscription license, maintenance contracts and active cloud services at the end of a reporting period.
  2. Maintenance Services ARR (M-ARR) represents the annualized value of active perpetual license maintenance service contracts at the end of the reporting period. 
  3. Subscription ARR (S-ARR) represents the annualized value of active subscription or term licenses at the end of a reporting period.
  4. Cloud ARR (C-ARR) represents the annualized value of active cloud services contracts at the end of a reporting period.
 
Non-GAAP Adjusted EBITDA
Set forth below is a reconciliation of the Company’s “Non-GAAP Adjusted EBITDA”
(Unaudited)
(In thousands except for per share data)
 
 Three Months Ended December 31,  Twelve Months Ended December 31, 
 2023  2022  2023  2022 
GAAP Net Loss from continuing operations$(542) $(2,339) $(7,010) $(9,918)
Interest expense 14   2   16   10 
Interest income (201)  (124)  (729)  (213)
Other expense 6      14   39 
Stock compensation 202   317   1,316   1,686 
Depreciation & amortization 85   75   335   325 
Severance and Furlough    100   178   100 
Tax expense 7   (116)  20   (116)
Non-GAAP Adjusted EBITDA$(429) $(2,085) $(5,860) $(8,087)
                


 Three Months Ended December 31,  Twelve Months Ended December 31, 
 2023  2022  2023  2022 
GAAP Net Loss from continuing operations$(542) $(2,339) $(7,010) $(9,918)
Adjustments to Net Loss:               
Severance and Furlough    100   178   100 
Non-GAAP Adjusted Net Loss from continuing operations$(542) $(2,239) $(6,832) $(9,818)
Net Loss per share from continuing operations —basic and diluted               
GAAP Loss from continuing operations, basic and diluted$(0.02) $(0.09) $(0.27) $(0.39)
Adjustments to Net Loss (as detailed above)    0.00   0.01   0.00 
Non-GAAP Adjusted Loss per share from continuing operations$(0.02) $(0.09) $(0.27) $(0.39)

FAQ

What was iCAD's annual recurring revenue for the fiscal year?

iCAD reported an annual recurring revenue of $8.7 million for the fiscal year.

What was the change in total revenues for Q4 2023 compared to the previous year?

Total revenues for Q4 2023 were $4.7 million, up 2% from the previous year.

Who is the President and CEO of iCAD?

Dana Brown is the President and CEO of iCAD.

What was the gross profit margin % in Q4 2023?

The gross profit margin % was 91% in Q4 2023.

What was the GAAP net loss from continuing operations in Q4 2023?

The GAAP net loss from continuing operations was ($0.5) million in Q4 2023.

iCAD, Inc.

NASDAQ:ICAD

ICAD Rankings

ICAD Latest News

ICAD Stock Data

42.73M
24.81M
5.82%
28.53%
1.71%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States of America
NASHUA

About ICAD

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.